Company intelligence / Profile preview

Dr. Program

Shibuya-ku, Tokyo, Japan

Ownership: Private
Development stage: Other

Overview

Dr. Program is a Japanese healthcare company specializing in the development and sale of high-performance skincare products and quasi-drugs. The company is best known for its 'Trinityline' brand, which leverages proprietary nanocapsule technology to improve the penetration and efficacy of active dermatological ingredients. Its product range focuses on anti-aging, deep hydration, and skin barrier restoration for sensitive or aging skin. In 2017, Dr. Program was acquired by Taisho Pharmaceutical, a leading Japanese pharmaceutical firm, to bolster its consumer health and functional cosmetics division.

Therapeutic areas: Dermatology
Modalities: NanoparticleSmall molecule
Industry: Non-Drug Biotech

Partnerships

Taisho Pharmaceutical

Beyond the preview

Go deeper on Dr. Program.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dr. Program.

Explore the full profile